QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 citigroup-downgrades-bio-techne-to-neutral-announces-85-price-target

Citigroup analyst Patrick Donnelly downgrades Bio-Techne (NASDAQ:TECH) from Buy to Neutral and announces $85 price target.

 molecular-instruments-announced-the-patents-court-of-england-and-wales-has-ordered-that-two-patents-owned-by-advanced-cell-diagnostics-a-bio-techne-company-both-be-revoked-advanced-cell-diagnostics-infringement-claims-against-molecular-instruments-are-dismissed-and-advanced-cell-diagnostics-make-a-costs-payment-of-172m-to-molecular-instruments

Molecular Instruments, Inc. announced that the Patents Court of the High Court of England and Wales has ordered: (1) that two p...

 which-large-cap-stocks-are-winning-this-earnings-season-15-stocks-to-watch-april-28-may-4-2024

Last week's top performers included Carvana, Pinterest, Moderna and JD.Com.

 benchmark-reiterates-buy-on-bio-techne-maintains-95-price-target

Benchmark analyst Robert Wasserman reiterates Bio-Techne (NASDAQ:TECH) with a Buy and maintains $95 price target.

 baird-maintains-outperform-on-bio-techne-raises-price-target-to-81

Baird analyst Catherine Schulte maintains Bio-Techne (NASDAQ:TECH) with a Outperform and raises the price target from $73 to...

 bio-techne-q3-adj-048-beats-045-estimate-sales-30343m-beat-29219m-estimate

Bio-Techne (NASDAQ:TECH) reported quarterly earnings of $0.48 per share which beat the analyst consensus estimate of $0.45 by 6...

Core News & Articles

Under this agreement, Thermo Fisher, through the European arm of its Fisher Scientific Channel, will distribute Bio-Techne'...

 bio-techne-and-novomol-dx-have-announced-the-development-of-bio-marker-pathfinder-an-ocular-biomarker-kit-as-a-point-of-care-application

The BMP kit runs on Bio-Techne's Ella™, a benchtop automated immunoassay platform leveraging Bio-Techne's R&D Syste...

 deutsche-bank-maintains-buy-on-bio-techne-lowers-price-target-to-82

Deutsche Bank analyst Justin Bowers maintains Bio-Techne (NASDAQ:TECH) with a Buy and lowers the price target from $85 to $82.

 bio-techne-surpasses-10k-peer-reviewed-publications-citing-rnascope-technology

Bio-Techne Corporation (NASDAQ:TECH) today announced that Advanced Cell Diagnostics (ACD), part of Bio-Techne's Spatial Bio...

 bio-techne-and-nikon-instruments-inc-announce-partnership-to-expand-access-to-innovative-spatial-biology-services

Bio-Techne Corporation (NASDAQ:TECH) is pleased to announce that Lunaphore, part of Bio-Techne's Spatial Biology Division, ...

Core News & Articles

By the end of today, February 26, 2024, Bio-Techne (NASDAQ:TECH) is set to deliver a dividend payout of $0.08 per share, equati...

 stephens--co-maintains-overweight-on-bio-techne-lowers-price-target-to-87

Stephens & Co. analyst Jacob Johnson maintains Bio-Techne (NASDAQ:TECH) with a Overweight and lowers the price target fr...